Shattuck Labs, Inc. (STTK)
| Market Cap | 808.93M +1,659.0% |
| Revenue (ttm) | 1,000,000 -66.6% |
| Net Income | -52.57M |
| EPS | -0.50 |
| Shares Out | 100.36M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 869,797 |
| Open | 8.01 |
| Previous Close | 7.90 |
| Day's Range | 7.93 - 8.15 |
| 52-Week Range | 0.92 - 8.33 |
| Beta | 1.11 |
| Analysts | Strong Buy |
| Price Target | 14.25 (+76.8%) |
| Earnings Date | Aug 11, 2026 |
About STTK
Shattuck Labs, Inc., a clinical-stage biotechnology company, engages in the development of antibodies for the treatment of inflammatory and immune-mediated diseases in the United States. The company develops SL-325, a death receptor 3 blocking monoclonal antibody, which is in Phase I clinical trial for the treatment of tumor necrosis factor like ligand 1A; and SL-425, a half-life extended version of SL-325, which is under IND-enabling chronic good laboratory practices toxicity study. It is also involved in the development of various preclinical... [Read more]
Financial Performance
In 2025, Shattuck Labs's revenue was $1.00 million, a decrease of -82.52% compared to the previous year's $5.72 million. Losses were -$48.81 million, -35.28% less than in 2024.
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for STTK stock is "Strong Buy." The 12-month stock price target is $14.25, which is an increase of 76.80% from the latest price.
News
Shattuck Labs initiated with a Strong Buy at Raymond James
Raymond James analyst Martin Auster initiated coverage of Shattuck Labs (STTK) with a Strong Buy rating and $18 price target SL-325 could offer a differentiated approach to the more than…
Shattuck Labs price target lowered to $14 from $18 at H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis lowered the firm’s price target on Shattuck Labs (STTK) to $14 from $18 and keeps a Buy rating on the shares after the company announced…
Shattuck Labs Quarterly report: Q2 2026
Shattuck Labs has published its Q2 2026 quarterly earnings report on August 11, 2026.
Shattuck Labs Earnings release: Q2 2026
Shattuck Labs released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Shattuck Labs reports Q2 EPS (12c), consensus (12c)
As of June 30, 2026, cash and cash equivalents and short-term investments were $208.3M, as compared to $50.5 million as of June 30, 2025, expected to fund operations into 2029.
Shattuck Labs initiated with an Overweight at JPMorgan
JPMorgan analyst Brian Cheng initiated coverage of Shattuck Labs (STTK) with an Overweight rating and $10 price target Shattuck is a clinical-stage biotech developing an anti-DR3 antibody program with...
Shattuck Labs initiated with an Outperform at Leerink
Leerink initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $16 price target The firm says the company has constructed a potentially differentiated pipeline centered around target...
Shattuck Labs initiated with an Outperform at Leerink
Leerink initiated coverage of Shattuck Labs (STTK) with an Outperform rating and $16 price target
Shattuck Labs Slides: Corporate presentation
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on July 14, 2026.
Shattuck Labs 10.9M share Spot Secondary priced at $4.00
The deal range was $4.00-$4.25. Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald acted as joint book running managers for the offering.
Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering
AUSTIN, Texas and DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs TBA Spot Secondary; price range $4.00-$4.25
Leerink, JPMorgan, Piper Sandler and Cantor Fitzgerald are acting as joint book running managers for the offering.
Shattuck Labs announces common stock offering, no amount given
Shattuck Labs (STTK) announced that it has commenced a public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded…
Shattuck Labs, Inc. Announces Proposed Public Offering
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (“Shattuck” or the “Company”) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of...
Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update
AUSTIN, Texas and DURHAM, N.C., June 09, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-...
Shattuck Labs price target raised to $18 from $7 at Citi
Citi raised the firm’s price target on Shattuck Labs (STTK) to $18 from $7 and keeps a Buy rating on the shares. The firm doubled SL-325 probability of success to…
Shattuck Labs price target raised to $17 from $14 at Needham
Needham raised the firm’s price target on Shattuck Labs (STTK) to $17 from $14 and keeps a Buy rating on the shares after the company announced topline results for its…
Shattuck Labs Transcript: Study result
SL-325 demonstrated strong safety, durable DR3 blockade, and a low 3.7% ADA rate in phase I, supporting extended dosing and a best-in-class immunogenicity profile. A phase II Crohn's trial will launch in Q3, and the bispecific SL-846 is advancing with promising preclinical data.
Shattuck Labs Press release: Study result
Shattuck Labs issued a press release on June 8, 2026, disclosing material business information to investors.
Shattuck Labs Slides: Study result
Shattuck Labs has posted slides in relation to its latest quarterly earnings report, which was published on June 8, 2026.
Shattuck Labs announces Phase 1 results for SL-325
Shattuck Labs (STTK) announced data from its Phase 1 clinical trial of SL-325, Shattuck’s lead DR3 blocking antibody candidate. Highlights included: Potentially best-in-mechanism immunogenicity profil...
Shattuck Labs Announces Phase 1 Results for SL-325
AUSTIN, TX and DURHAM, NC, June 08, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck or the Company) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentia...
Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8
AUSTIN, Texas and DURHAM, N.C., June 05, 2026 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of potentially first-...
Citi opens ‘upside 30-day catalyst watch’ on Shattuck into data
Citi added an “upside 30-day catalyst watch” on Shattuck Labs (STTK) after upgrading the shares to Buy with a $7 price target into the Q2 Phase 1 data for SL-325…